Autism and Pervasive Developmental Disorders – Cannabis THC : CBD Ratios

Autism and Pervasive Developmental Disorders Research Dashboard

16

Primary Studies

2

Related Studies

18

Total Studies

Clinical Studies

2

Double-blind human trials

3

Clinical human trials

Pre-Clinical Studies

8

Meta-analyses/Reviews

2

Animal studies

1

Laboratory studies

What am I missing as a non-subscriber?

To see a full dashboard with study details and filtering, go to our DEMO page.

As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.

CannaKeys has 18 studies associated with Autism and Pervasive Developmental Disorders.

Here is a small sampling of Autism and Pervasive Developmental Disorders studies by title:


Components of the Autism and Pervasive Developmental Disorders Research Dashboard

  • Dosing information available for Autism and Pervasive Developmental Disorders
  • Chemotype guidance for treating Autism and Pervasive Developmental Disorders with cannabis
  • Synopsis of cannabis research for Autism and Pervasive Developmental Disorders
  • Individual study details for Autism and Pervasive Developmental Disorders

Ready to become a subscriber? Go to our PRICING page.

Select New Condition

Search By Keyword

Filter Condition

Members can filter by the following criteria:

  • Study Type
  • Chemotype
  • Cannabinoids & Endocannabinoids
  • Terpenes
  • Receptors
  • Ligands
  • Study Result
  • Year of Publication

Overview - Autism and Pervasive Developmental Disorders

Description of Autism and Pervasive Developmental Disorders

Thirty years ago few people had ever heard the word autism. Circa 1975, only one in 5,000 children was diagnosed with this condition. Nowadays it is a household word, and almost everybody knows of someone suffering from the disease. The allopathic community considers autism a neurodevelopmental disorder that begins in very early childhood. Government statistics suggest that the prevalence rate of autism is increasing 10-17% annually, doubling roughly every five years since 1980. The facts are starkly clear: the pervasiveness of autism is growing exponentially. If current trends continue and no cure is found, we could be looking at a future reality where, by 2047, one in two people will be diagnosed as autistic. Pharmaceutical medications (such as Ritalin, an amphetamine-like drug) are given to millions of children every year to control symptoms.

Disease Classification

Condition: Autism
Disease Family: Mental Disorders
Organ System: Mental/Emotional System
ICD-10 Chapter: Mental and Behavioural Disorders
ICD-10 Code: F84

Autism and Pervasive Developmental Disorders Symptoms:

Symptoms of autism fall on a spectrum range between the following: the autism savant, atypical social interaction, atypical communicating, atypical interests, compulsive behavior, destructive behavior

Also known as:

ASD, Infantile Autism, Childhood onset autism

Drug Interactions

THC Interaction with Pharmaceutical Drugs

  • THC can enhance the effects of drugs that cause sedation and depress the central nervous system, such as benzodiazepines, barbiturates, and alcohol, for example. 
  • THC is metabolized by and an inhibitor of a number of enzymatic liver pathways referred to as cytochrome P450. There are more than 50 enzymes belonging to this enzyme family, a number of which are responsible for the breakdown of common drugs such as antidepressants (e.g. amitriptyline, doxepine, fluvoxamine), antipsychotics (haloperidol, clozapine, stelazine), or beta-blockers (propranolol, theophylline, warfarin).  Thus patients taking these classes of medication may find that THC increases the concentration and effects of these drugs as well as the duration of their effects.
  • Clinical observation suggests no likely interactions with other pharmaceuticals at a total daily dose of up to 20mg THC.

CBD Interaction with Pharmaceutical Drugs

  • CBD may alter action on metabolic enzymes (certain drug-transport mechanisms), and as such may alter interactions with other drugs, some of which may produce therapeutic or adverse effects. For instance, CBD interacts with the enzyme cytochrome P450 3A4 and cytochrome P450 2C19, increasing the bioavailability of anti-epileptic drugs such as clobazam (a benzodiazepine). This makes it possible to achieve the same results at significantly lower dosages, reducing treatment costs and risks of adverse effects. 
  • Groups of drugs affected include: anti-epileptic drugs, psychiatric drugs, and drugs affecting metabolic enzymes, for example.
  • Clinical observations suggest no likely interactions with other pharmaceuticals at a total daily dose of up to 100mg CBD

Dosing Considerations

THC Dosage Considerations

  • THC micro dose:  0.1 mg to 0.4 mg (0.001mg/kg to 0.005mg/kg)
  • THC low dose:  0.5 mg to 5 mg (0.006mg/kg to 0.06mg/kg)
  • THC medium dose:  6 mg to 20 mg (0.08mg/kg to 0.27mg/kg)
  • THC high dose:  21 mg to 50+ mg (0.28mg/kg to 0.67mg/kg)
Formula for converting a set dose into mg/kg considerations: mg ÷ kg = mg/kg
(sample conversion calculated on a person weighing 75kg)

CBD Dosage Considerations

  • CBD low dose:  0.4 mg to 19 mg (0.005mg/kg to 0.25mg/kg)
  • CBD medium dose: 20 mg to 99 mg (0.26mg/kg to 1.32mg/kg)
  • CBD high dose:  100 mg to 800+ mg (1.33mg/kg to 10.7mg/kg)
  • (upper limits tested ~1,500mg)
Formula for converting a set dose into mg/kg considerations: mg ÷ kg = mg/kg
(sample conversion calculated on a person weighing 75kg)
Top

Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.

Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.